Holen Sie sich die Stockscreener-App
330.11
3.37%
-11.53
Handel nachbörslich:
330.22
0.11
+0.03%
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Forum
Prognose
Aktiensplit
Dividendenhistorie
Schlusskurs vom Vortag:
$341.64
Offen:
$337.76
24-Stunden-Volumen:
2.74M
Relative Volume:
1.06
Marktkapitalisierung:
$177.76B
Einnahmen:
$35.89B
Nettoeinkommen (Verlust:
$7.01B
KGV:
25.52
EPS:
12.9352
Netto-Cashflow:
$11.54B
1W Leistung:
+0.86%
1M Leistung:
+2.76%
6M Leistung:
+11.15%
1J Leistung:
+24.94%
1-Tages-Spanne:
$328.21
$341.46
1-Wochen-Bereich:
$318.21
$343.05
52-Wochen-Spanne:
$260.55
$346.38
Amgen Inc Stock (AMGN) Company Profile
Firmenname
Amgen Inc
Sektor
Telefon
(805)447-1000
Adresse
ONE AMGEN CENTER DRIVE, THOUSAND OAKS, CA
Vergleichen Sie AMGN mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
AMGN
Amgen Inc
|
330.11 | 183.97B | 35.89B | 7.01B | 11.54B | 12.94 |
|
LLY
Lilly Eli Co
|
1,085.19 | 991.76B | 59.42B | 18.41B | 6.44B | 20.22 |
|
JNJ
Johnson Johnson
|
205.75 | 499.90B | 92.15B | 25.12B | 20.46B | 10.36 |
|
ABBV
Abbvie Inc
|
224.13 | 412.54B | 59.64B | 2.36B | 19.68B | 1.3253 |
|
MRK
Merck Co Inc
|
110.99 | 269.55B | 63.90B | 19.05B | 13.05B | 7.5596 |
|
NVS
Novartis Ag Adr
|
141.46 | 272.43B | 54.45B | 14.42B | 17.15B | 7.333 |
Amgen Inc Stock (AMGN) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-01-07 | Fortgesetzt | UBS | Buy |
| 2025-12-05 | Hochstufung | Erste Group | Hold → Buy |
| 2025-11-24 | Fortgesetzt | Truist | Hold |
| 2025-11-13 | Eingeleitet | Scotiabank | Sector Outperform |
| 2025-09-03 | Fortgesetzt | Raymond James | Mkt Perform |
| 2025-05-20 | Fortgesetzt | Guggenheim | Neutral |
| 2025-04-22 | Fortgesetzt | Cantor Fitzgerald | Neutral |
| 2024-12-10 | Fortgesetzt | BofA Securities | Underperform |
| 2024-11-15 | Eingeleitet | Wolfe Research | Peer Perform |
| 2024-11-14 | Eingeleitet | Citigroup | Neutral |
| 2024-10-17 | Eingeleitet | Bernstein | Outperform |
| 2024-10-14 | Herabstufung | Truist | Buy → Hold |
| 2024-09-27 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2024-08-07 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2024-05-03 | Hochstufung | Barclays | Underweight → Equal Weight |
| 2024-05-03 | Hochstufung | William Blair | Mkt Perform → Outperform |
| 2024-03-28 | Fortgesetzt | Raymond James | Mkt Perform |
| 2024-02-07 | Herabstufung | Leerink Partners | Outperform → Market Perform |
| 2023-12-21 | Hochstufung | Daiwa Securities | Neutral → Buy |
| 2023-12-19 | Hochstufung | BMO Capital Markets | Market Perform → Outperform |
| 2023-12-12 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2023-11-09 | Eingeleitet | Deutsche Bank | Hold |
| 2023-11-02 | Hochstufung | Truist | Hold → Buy |
| 2023-10-20 | Fortgesetzt | JP Morgan | Neutral |
| 2023-10-17 | Fortgesetzt | Morgan Stanley | Equal-Weight |
| 2023-10-11 | Fortgesetzt | BofA Securities | Neutral |
| 2023-09-06 | Eingeleitet | HSBC Securities | Buy |
| 2023-04-24 | Bestätigt | Oppenheimer | Outperform |
| 2023-03-13 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2023-02-13 | Bestätigt | Truist | Buy |
| 2022-11-18 | Eingeleitet | Credit Suisse | Underperform |
| 2022-10-31 | Herabstufung | Barclays | Equal Weight → Underweight |
| 2022-10-11 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2022-05-23 | Eingeleitet | SVB Leerink | Mkt Perform |
| 2022-02-09 | Bestätigt | Barclays | Equal Weight |
| 2022-02-09 | Bestätigt | Jefferies | Buy |
| 2022-02-09 | Bestätigt | Morgan Stanley | Equal-Weight |
| 2022-02-09 | Bestätigt | Oppenheimer | Outperform |
| 2022-02-09 | Bestätigt | Wells Fargo | Equal Weight |
| 2022-01-05 | Herabstufung | BofA Securities | Buy → Neutral |
| 2021-12-09 | Fortgesetzt | Wells Fargo | Equal Weight |
| 2021-12-06 | Eingeleitet | Goldman | Buy |
| 2021-11-19 | Eingeleitet | BMO Capital Markets | Market Perform |
| 2021-09-23 | Herabstufung | Daiwa Securities | Outperform → Neutral |
| 2021-09-07 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2020-12-29 | Eingeleitet | Daiwa Securities | Buy |
| 2020-10-28 | Eingeleitet | UBS | Neutral |
| 2020-10-26 | Hochstufung | Raymond James | Mkt Perform → Outperform |
| 2020-10-12 | Hochstufung | Truist | Hold → Buy |
| 2020-10-09 | Herabstufung | Bernstein | Outperform → Mkt Perform |
| 2020-10-09 | Herabstufung | Truist | Buy → Hold |
| 2020-10-08 | Herabstufung | Raymond James | Outperform → Mkt Perform |
| 2020-04-15 | Fortgesetzt | Guggenheim | Neutral |
| 2020-03-31 | Eingeleitet | Wolfe Research | Peer Perform |
| 2020-03-30 | Hochstufung | Raymond James | Mkt Perform → Outperform |
| 2020-03-05 | Hochstufung | BofA/Merrill | Neutral → Buy |
| 2020-02-27 | Eingeleitet | Barclays | Equal Weight |
| 2020-01-31 | Herabstufung | Robert W. Baird | Neutral → Underperform |
| 2020-01-21 | Hochstufung | Evercore ISI | In-line → Outperform |
| 2019-12-24 | Eingeleitet | Raymond James | Mkt Perform |
| 2019-12-17 | Fortgesetzt | Morgan Stanley | Overweight |
| 2019-11-12 | Eingeleitet | SunTrust | Buy |
| 2019-11-05 | Hochstufung | Cantor Fitzgerald | Neutral → Overweight |
| 2019-10-17 | Fortgesetzt | BofA/Merrill | Neutral |
| 2019-08-19 | Herabstufung | Mizuho | Buy → Neutral |
| 2019-05-23 | Hochstufung | Citigroup | Neutral → Buy |
Alle ansehen
Amgen Inc Aktie (AMGN) Neueste Nachrichten
Amgen (NASDAQ:AMGN) Price Target Raised to $319.00 at Truist Financial - MarketBeat
Amgen Advances Leukemia Strategy With Completed Blinatumomab Study in Japan - TipRanks
Should Amgen’s (AMGN) Exclusive DISCO Oncology Deal Require Action From Investors? - Yahoo Finance
Amgen acquires British Dark Blue Therapeutics for USD 840m - medwatch.com
SG Americas Securities LLC Has $79.95 Million Stake in Amgen Inc. $AMGN - MarketBeat
Amgen Inc. $AMGN Shares Acquired by HB Wealth Management LLC - MarketBeat
Evotec benefits from Dark Blue acquisition by Amgen - European Biotechnology Magazine
Biotech Amgen acquires UK-based Dark Blue Therapeutics in $840m deal - Silicon Republic
Amgen Inc.: How a Biotech Powerhouse Is Re-Architecting Its Drug Platform for the Next Decade - AD HOC NEWS
Amgen Inc. $AMGN Shares Acquired by Benjamin Edwards Inc. - MarketBeat
Call for Application for 2026 Tsinghua Amgen Scholars Program - PR Newswire
Humira Market to Witness Remarkable Growth With AbbVie Inc., Amgen Inc., Samsung Bioepis - openPR.com
AMGEN TO PRESENT AT THE 44TH ANNUAL J.P. MORGAN HEALTHCARE CONFERENCE - PR Newswire
Amgen Inc.: How a Biotech Veteran Is Re?Engineering Its Own Future - AD HOC NEWS
Amgen Buys Dark Blue In $840 Million Bet On New Leukemia Drugs - Benzinga
Amgen Advances Early-Stage Obesity Candidate With New Injection Trial - TipRanks
Amgen Buys Dark Blue Therapeutics to Strengthen Oncology Pipeline - Finviz
UBS Raises Amgen (AMGN) Price Target to $380 and Upgrades to Buy - GuruFocus
Amgen acquires cancer drugmaker Dark Blue Therapeutics for up to $840 mn - ETPharma.com
Amgen buys Dark Blue Therapeutics in $840m oncology deal - Yahoo Finance
Robeco Institutional Asset Management B.V. Has $123.48 Million Stock Position in Amgen Inc. $AMGN - MarketBeat
UBS assumes coverage on Amgen stock with Buy rating, $380 price target - Investing.com UK
Amgen (NASDAQ:AMGN) Is Increasing Its Dividend To $2.52 - simplywall.st
Cerity Partners LLC Sells 6,837 Shares of Amgen Inc. $AMGN - MarketBeat
DISCO Pharmaceuticals Enters License Agreement to Advance Novel Cancer Surfaceome Targeted Therapies - GlobeNewswire Inc.
CWA Asset Management Group LLC Sells 14,786 Shares of Amgen Inc. $AMGN - MarketBeat
Amgen Acquires Dark Blue Therapeutics In Deal Valued At Up To $840 Million - Pulse 2.0
Amgen Acquires Dark Blue in $840 Million Deal to Pursue Innovative Leukemia Treatments - Bitget
Amgen adds AML candidate in deal for U.K.-based Dark Blue: Deals Report - BioCentury
UBS Upgrades Amgen (AMGN) to Buy, Raises Price Target to $380 - GuruFocus
Amgen upgraded to buy at UBS on potential of MariTide, olpasiran - Seeking Alpha
Amgen Paints Pipeline Dark Blue In Acquisition of Small Molecule Developer - Citeline News & Insights
Amgen’s Own High Court Loss Cited in Pushback to Evenity Claims - Bloomberg Law News
Amgen Agrees to Buy Dark Blue Therapeutics in Up to $840 Million Deal - GuruFocus
Amgen swoops on UK cancer biotech in deal worth up to $840mn - Financial Times
Amgen buys protein-degrading startup Dark Blue for up to $840M - BioPharma Dive
$840 million Dark Blue buy hands Amgen AML drug - The Pharma Letter
Amgen buys UK biotech Dark Blue Therapeutics for up to $840m - Sharecast.com
Amgen to buy blood cancer biotech Dark Blue Therapeutics in $840M deal - Axios
Amgen acquires Dark Blue Therapeutics, bolstering oncology pipeline - MarketScreener
Amgen adds preclinical cancer asset via $840M deal for Dark Blue Therapeutics - FirstWord Pharma
Amgen Buys Dark Blue Therapeutics in Deal Worth Up to $840 Million - MarketScreener
Amgen (AMGN) Acquires Dark Blue Therapeutics for $840 Million - GuruFocus
Amgen acquires Dark Blue Therapeutics for up to $840 million - Investing.com
Dark Blue Therapeutics acquired by Amgen for up to $840 million - MarketScreener
Amgen (AMGN) Expands Oncology Portfolio with Acquisition of Dark Blue Therapeutics - GuruFocus
Amgen acquires Dark Blue Therapeutics for up to $840 million By Investing.com - Investing.com Canada
Amgen Acquires Privately-held Dark Blue Therapeutics In $840 Mln Deal - Nasdaq
New acute leukemia approach behind Amgen's $840M acquisition - Stock Titan
Zenas’s Obexelimab Meets Phase III Endpoint In IgG4-RD But Trails Amgen Rival - Citeline News & Insights
AMGEN ACQUIRES DARK BLUE THERAPEUTICS, BOLSTERING ONCOLOGY PIPELINE - PR Newswire
Finanzdaten der Amgen Inc-Aktie (AMGN)
Umsatz
Nettogewinn
Free Cashflow
ENV
2.96%
0.04%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):